Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 9Gynecologic 2Tumor-Agnostic 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Ovarian Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Endometrial Neoplasms 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 134pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Letrozole 28Drug Therapy 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23durvalumab 22Albumin-Bound Paclitaxel 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20Specimen Handling 20Filgrastim 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × inavolisib × Gynecologic × Clear all
NCT07522697 2026-04-13

MITO END-4

National Cancer Institute, Naples

Phase 2 Not yet recruiting
48 enrolled
Gynecologic

Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms

NCT04931342 2026-03-10

BOUQUET

Hoffmann-La Roche

Phase 2 Active not recruiting
176 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡